Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nalbuphine Sebacate
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LT1001 is the world's first week-long extended-release analgesic injection. The approval from Singapore has significance in accelerating the introduction of LT1001 in Southeast Asia.
Brand Name : LT1001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 21, 2020
Lead Product(s) : Nalbuphine Sebacate
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?